These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 12609962)

  • 1. MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models.
    Mahon FX; Belloc F; Lagarde V; Chollet C; Moreau-Gaudry F; Reiffers J; Goldman JM; Melo JV
    Blood; 2003 Mar; 101(6):2368-73. PubMed ID: 12609962
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tyrosine kinase inhibitor resistance in chronic myeloid leukemia cell lines: investigating resistance pathways.
    Tang C; Schafranek L; Watkins DB; Parker WT; Moore S; Prime JA; White DL; Hughes TP
    Leuk Lymphoma; 2011 Nov; 52(11):2139-47. PubMed ID: 21718141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Silencing of suppressor of cytokine signaling-3 due to methylation results in phosphorylation of STAT3 in imatinib resistant BCR-ABL positive chronic myeloid leukemia cells.
    Al-Jamal HA; Jusoh SA; Yong AC; Asan JM; Hassan R; Johan MF
    Asian Pac J Cancer Prev; 2014; 15(11):4555-61. PubMed ID: 24969884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro studies of the combination of imatinib mesylate (Gleevec) and arsenic trioxide (Trisenox) in chronic myelogenous leukemia.
    La Rosée P; Johnson K; O'Dwyer ME; Druker BJ
    Exp Hematol; 2002 Jul; 30(7):729-37. PubMed ID: 12135670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Olmutinib Reverses Doxorubicin Resistance in ETS1-Overexpressing Leukemia Cells.
    Zhong J; Zhang J; Yu X; Zhang X; Dian L
    Med Sci Monit; 2020 Aug; 26():e924922. PubMed ID: 32830792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML.
    O'Hare T; Pollock R; Stoffregen EP; Keats JA; Abdullah OM; Moseson EM; Rivera VM; Tang H; Metcalf CA; Bohacek RS; Wang Y; Sundaramoorthi R; Shakespeare WC; Dalgarno D; Clackson T; Sawyer TK; Deininger MW; Druker BJ
    Blood; 2004 Oct; 104(8):2532-9. PubMed ID: 15256422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance.
    Mahon FX; Deininger MW; Schultheis B; Chabrol J; Reiffers J; Goldman JM; Melo JV
    Blood; 2000 Aug; 96(3):1070-9. PubMed ID: 10910924
    [TBL] [Abstract][Full Text] [Related]  

  • 8. XIAP and P-glycoprotein co-expression is related to imatinib resistance in chronic myeloid leukemia cells.
    Silva KL; de Souza PS; Nestal de Moraes G; Moellmann-Coelho A; Vasconcelos Fda C; Maia RC
    Leuk Res; 2013 Oct; 37(10):1350-8. PubMed ID: 23891189
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571.
    Donato NJ; Wu JY; Stapley J; Gallick G; Lin H; Arlinghaus R; Talpaz M
    Blood; 2003 Jan; 101(2):690-8. PubMed ID: 12509383
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imatinib mesylate (STI571) abrogates the resistance to doxorubicin in human K562 chronic myeloid leukemia cells by inhibition of BCR/ABL kinase-mediated DNA repair.
    Majsterek I; Sliwinski T; Poplawski T; Pytel D; Kowalski M; Slupianek A; Skorski T; Blasiak J
    Mutat Res; 2006 Jan; 603(1):74-82. PubMed ID: 16388976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression.
    Mahon FX; Hayette S; Lagarde V; Belloc F; Turcq B; Nicolini F; Belanger C; Manley PW; Leroy C; Etienne G; Roche S; Pasquet JM
    Cancer Res; 2008 Dec; 68(23):9809-16. PubMed ID: 19047160
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia.
    Dulucq S; Bouchet S; Turcq B; Lippert E; Etienne G; Reiffers J; Molimard M; Krajinovic M; Mahon FX
    Blood; 2008 Sep; 112(5):2024-7. PubMed ID: 18524988
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overexpression of P-glycoprotein in K562 cells does not confer resistance to the growth inhibitory effects of imatinib (STI571) in vitro.
    Ferrao PT; Frost MJ; Siah SP; Ashman LK
    Blood; 2003 Dec; 102(13):4499-503. PubMed ID: 12881321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapid detection of phosphotyrosine proteins by flow cytometric analysis in Bcr-Abl-positive cells.
    Desplat V; Lagarde V; Belloc F; Chollet C; Leguay T; Pasquet JM; Praloran V; Mahon FX
    Cytometry A; 2004 Nov; 62(1):35-45. PubMed ID: 15468123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia.
    Wolff NC; Veach DR; Tong WP; Bornmann WG; Clarkson B; Ilaria RL
    Blood; 2005 May; 105(10):3995-4003. PubMed ID: 15657179
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of MDR1 does not sensitize primitive chronic myeloid leukemia CD34+ cells to imatinib.
    Hatziieremia S; Jordanides NE; Holyoake TL; Mountford JC; Jørgensen HG
    Exp Hematol; 2009 Jun; 37(6):692-700. PubMed ID: 19394750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene expression profiling of imatinib and PD166326-resistant CML cell lines identifies Fyn as a gene associated with resistance to BCR-ABL inhibitors.
    Grosso S; Puissant A; Dufies M; Colosetti P; Jacquel A; Lebrigand K; Barbry P; Deckert M; Cassuto JP; Mari B; Auberger P
    Mol Cancer Ther; 2009 Jul; 8(7):1924-33. PubMed ID: 19567819
    [TBL] [Abstract][Full Text] [Related]  

  • 18. P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate.
    Illmer T; Schaich M; Platzbecker U; Freiberg-Richter J; Oelschlägel U; von Bonin M; Pursche S; Bergemann T; Ehninger G; Schleyer E
    Leukemia; 2004 Mar; 18(3):401-8. PubMed ID: 14724652
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2.
    Dai Y; Rahmani M; Corey SJ; Dent P; Grant S
    J Biol Chem; 2004 Aug; 279(33):34227-39. PubMed ID: 15175350
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Berbamine exhibits potent antitumor effects on imatinib-resistant CML cells in vitro and in vivo.
    Wei YL; Xu L; Liang Y; Xu XH; Zhao XY
    Acta Pharmacol Sin; 2009 Apr; 30(4):451-7. PubMed ID: 19270722
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.